Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Change history 25 March 2026 A Correction to this paper has been published: Abbreviations AOM: Anti-obesity medication WMD: Weighted mean difference CI: Confidence interval SD: Standard deviation RCT: Randomized controlled trial GLP-1 RA: Glucagon-like peptide 1 receptor agonist GIP: Glucose-dependent insulinotropic polypeptide GCCR: Glucagon receptor BMI: Body mass index References World Obesity Federation
We thank Novo Nordisk for generously supplying the liraglutide used in these projects
A1C reduction comparison A network meta-analysis published in BMC Endocrine Disorders in 2024, analyzing 26 clinical studies, found the following A1C reductions compared to placebo: Tirzepatide 15mg: -2.24% A1C reduction Tirzepatide 10mg: -1.99% A1C reduction Tirzepatide 5mg: -1.82% A1C reduction Liraglutide 1.8mg: approximately -1.3% A1C reduction Liraglutide 1.2mg: -1.23% A1C reduction At the highest respective doses, tirzepatide reduces A1C by nearly twice as much as liraglutide
Mikus, D., Grabarevic, Z., Rucman, R., Petek, M., Turkovic, B., Rokotov, D
Safety Considerations The combination of GLP-1 medications and statins is well-tolerated by most patients
US$ 28.23
US$ 28.57
US$ 21.03
US$ 27.56
US$ 25.46
US$ 28.64
